Korean J Clin Neurophysiol.  2016 Jun;18(1):14-17. 10.14253/kjcn.2016.18.1.14.

Pulmonary Thromboembolism after Intravenous Immunoglobulin Therapy in Guillain-Barre Syndrome

• Park JM
• Kim NK
• Park JS

• KMID: 2328823
• DOI: http://doi.org/10.14253/kjcn.2016.18.1.14

Abstract

Intravenous immunoglobulin (IVIG) is a safe treatment to treat various neurological disorders, but fatal thrombotic events as rare complications have been reported. A 54-year-old woman with Guillain-Barre syndrome complained of dyspnea during IVIG treatment. She was finally diagnosed with pulmonary thromboembolism. To the best of our knowledge, this is the first case of pulmonary thromboembolism associated with IVIG treatment in a Korean patient with Guillain-Barre syndrome.

Keyword

Guillain-Barre syndrome; Intravenous immunoglobulin; Pulmonary thromboembolism

MeSH Terms

Dyspnea
Female
Guillain-Barre Syndrome*
Humans
Immunization, Passive*
Immunoglobulins*
Immunoglobulins, Intravenous
Middle Aged
Nervous System Diseases
Pulmonary Embolism*
Immunoglobulins
Immunoglobulins, Intravenous

Figure

• 

  Figure 1. The baseline and follow up electrocardiography of the patient. The initial electrocardiography was unremarkable (A) but follow up electrocardiography performed after dyspnea had a significant change showing S1Q3T3 pattern (prominent S wave in lead I, Q wave and inverted T wave in lead III), T wave inversion in leads V1-V6 V1-V6 (thin arrows) (B), The axial sections of CT scan showed prominent bilateral pulmonary thromboembolism pulmonary thromboembolism (white arrows) (C) and a deep vein thrombosis in the left deep popliteal vein popliteal vein (white arrow) (D). CT; computed tomography.

Reference

1.Willison HJ., Jacobs BC., van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Feb 19. [Epub].http://dx.doi.org/10.1016/S0140-6736(16)00339-1.

2.Brannagan TH 3rd., Nagle KJ., Lange DJ., Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology. 1996. 47:674–677.

3.Marie I., Maurey G., Herve F., Hellot MF., Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006. 155:714–721.

4.Stangel M., Kiefer R., Pette M., Smolka MN., Marx P., Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders- a prospective study. J Neurol. 2003. 250:818–821.

5.Wolberg AS., Kon RH., Monroe DM., Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000. 65:30–34.

6.Voltz R., Rosen FV., Yousry T., Beck J., Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology. 1996. 46:250–251.

7.Paran D., Herishanu Y., Elkayam O., Shopin L., Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005. 16:313–318.

8.Rajabally YA., Kearney DA. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study. J Neurol Sci. 2011. 308:124–127.

9.Lee YJ., Shin JU., Lee J., Kim K., Kim WS., Ahn JS, et al. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy. J Korean Med Sci. 2007. 22:758–761.

10.Kang SY., Kang JH., Kim JS. A case of cerebral infarction following intravenous immunoglobulin therapy in a patient with Guillain-Barre syndrome. J Korean Neurol Assoc. 2003. 21:217–219.